Capitalizing on the isogenic models of B cell lymphomas expressing IRF8 WT, N87Y, and I424T that we developed, we then tested whether these IRF8 mutants lose their promoter binding capacity. The gene discussed is IRF8; the disease is B-cell non-Hodgkin lymphoma.